Brandes Investment Partners LP Sells 49,921 Shares of Takeda Pharmaceutical Co. $TAK

Brandes Investment Partners LP trimmed its position in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 1.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,881,882 shares of the company’s stock after selling 49,921 shares during the quarter. Brandes Investment Partners LP owned approximately 0.12% of Takeda Pharmaceutical worth $60,519,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Private Trust Co. NA boosted its position in Takeda Pharmaceutical by 84.7% during the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after acquiring an additional 783 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in Takeda Pharmaceutical by 56.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after acquiring an additional 1,292 shares in the last quarter. Harbour Investments Inc. boosted its position in Takeda Pharmaceutical by 300.3% during the 4th quarter. Harbour Investments Inc. now owns 4,612 shares of the company’s stock valued at $72,000 after acquiring an additional 3,460 shares in the last quarter. Manchester Capital Management LLC boosted its position in Takeda Pharmaceutical by 91.4% during the 4th quarter. Manchester Capital Management LLC now owns 4,649 shares of the company’s stock valued at $72,000 after acquiring an additional 2,220 shares in the last quarter. Finally, Advisory Services Network LLC bought a new stake in Takeda Pharmaceutical during the 3rd quarter valued at approximately $74,000. 9.17% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Sanford C. Bernstein raised Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research report on Wednesday, April 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Takeda Pharmaceutical in a research report on Wednesday, April 29th. Wall Street Zen cut Takeda Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 16th. Finally, Zacks Research raised Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 3rd. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Takeda Pharmaceutical currently has an average rating of “Moderate Buy”.

Takeda Pharmaceutical Price Performance

TAK stock opened at $15.70 on Wednesday. The firm has a 50 day moving average price of $16.88 and a 200-day moving average price of $16.68. Takeda Pharmaceutical Co. has a 52-week low of $12.99 and a 52-week high of $18.90. The firm has a market capitalization of $49.95 billion, a price-to-earnings ratio of 40.24 and a beta of -0.07. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.70 and a current ratio of 1.27.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. Takeda Pharmaceutical had a net margin of 4.31% and a return on equity of 11.07%. The firm had revenue of $6.90 billion during the quarter. Equities research analysts forecast that Takeda Pharmaceutical Co. will post 1.56 EPS for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.